Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
KAKurt A. SchalperMEMaría E. Rodríguez-RuizRDRicardo Díez-ValleÁLÁlvaro López‐JaneiroAPAngelo Porciuncula
Yale University · Navarre Institute of Health Research · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
657
total citations
- FWCI
- 56.51
- Percentile
- 100%
- References
- 41
Citations per year
Authors
20- KAKurt A. SchalperCorresponding
Yale University
- MEMaría E. Rodríguez-Ruiz
Navarre Institute of Health Research, Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer
- RDRicardo Díez-Valle
Clinica Universidad de Navarra
- ÁLÁlvaro López‐Janeiro
Clinica Universidad de Navarra
- APAngelo Porciuncula
Yale University
Topics & keywords
Topics
Keywords
- Nivolumab
- Medicine
- Adjuvant
- Tumor microenvironment
- Oncology
- Immunotherapy
- Immune system
- Immune checkpoint
UN Sustainable Development Goals
- Zero hunger
No related works found for this paper.